Alterations in intratumoral and peripheral immune status in recurrent gliomas and their prognostic implications for patients underwent reoperation

被引:1
|
作者
Ou, Ailian [1 ,2 ]
Hu, Wanming [2 ,3 ]
Jiang, Pingping [4 ]
Lu, Jie [1 ,2 ]
Zheng, Yongqiang [2 ]
Ke, Chao [1 ,2 ]
Mou, Yonggao [1 ,2 ]
Sai, Ke [1 ,2 ]
Li, Depei [1 ,2 ]
机构
[1] Sun Yat Sen Univ, Canc Ctr, Dept Neurosurg & Neurooncol, Guangzhou 510060, Peoples R China
[2] Sun Yat Sen Univ, Guangdong Prov Clin Res Ctr Canc, Canc Ctr, State Key Lab Oncol South China, Guangzhou 510060, Peoples R China
[3] Sun Yat Sen Univ, Canc Ctr, Dept Pathol, Guangzhou 510060, Peoples R China
[4] Guangdong Pharmaceut Univ, Affiliated Hosp 1, Dept Tradit Chinese Med, Guangzhou 510080, Peoples R China
基金
中国国家自然科学基金;
关键词
Recurrent gliomas; Prognosis; Tumor associated macrophage; Systemic inflammatory index; Metabolic reprogramming; GLIOBLASTOMA; EVOLUTION; METABOLISM; THERAPY; CELLS; GENE;
D O I
10.1016/j.intimp.2024.112797
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Reoperation is a treatment option for recurrent gliomas, yet factors impacting survival following reoperation remain poorly defined. Tumor immunity is profoundly associated with disease progression. Here, we analyze the immune status characteristics and their prognostic implications in recurrent gliomas. Methods: Intratumoral and peripheral immune characteristics between primary and recurrent gliomas were compared by conducting immunohistological staining and hematological examination with our in-house samples, and analyzing bulk and single-cell sequencing data from publicly available sources. Survival analysis was conducted to identify immunological markers with prognostic significances. Results: We observed a significant reduction in peripheral lymphocyte count, while an elevation in neutrophil-tolymphocyte ratio (NLR) and red cell distribution width-to-platelet ratio (RPR) in patients with recurrent gliomas than in newly-diagnosed patients. Higher NLR and RPR indicated worse survival following reoperation in recurrent patients. Transcriptomic and immunohistological analysis showed an increased infiltration of tumor- associated macrophages (TAMs) and CD8+ + T cell in recurrent gliomas compared to primary gliomas in both IDH-wildtype and mutant subtypes. Moreover, the abundance of TAMs emerged as an independent indicator for an inferior prognosis in recurrent gliomas. Single-cell profiling revealed a significant heterogeneity in the phenotypes of TAMs between primary and recurrent gliomas. Notably, TAMs enriched in recurrent gliomas exhibited elevated expression of interferon-gamma-induced genes, multiple immunosuppressive molecules (TGFB1, CD276), and increased activity in glycose and lipid metabolism, indicating metabolic reprogramming. Conclusion: Recurrent gliomas demonstrate augmented immune cell infiltration, but they fail to overcome TAMsinduced immunosuppression. Immunosuppressive indices, including TAM abundance, peripheral NLR and RPR, have prognostic implications for recurrent gliomas.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] The outcomes and prognostic factors of patients who underwent reoperation for persistent/recurrent papillary thyroid carcinoma
    Wenyu Sun
    Lu Di
    Lili Chen
    Duanshu Li
    Yi Wu
    Jun Xiang
    Shichong Zhou
    Tuanqi Sun
    BMC Surgery, 22
  • [2] The outcomes and prognostic factors of patients who underwent reoperation for persistent/recurrent papillary thyroid carcinoma
    Sun, Wenyu
    Di, Lu
    Chen, Lili
    Li, Duanshu
    Wu, Yi
    Xiang, Jun
    Zhou, Shichong
    Sun, Tuanqi
    BMC SURGERY, 2022, 22 (01)
  • [3] Reoperation in recurrent high-grade gliomas - Literature review of prognostic factors and outcome
    Brandes, AA
    Vastola, F
    Monfardini, S
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1999, 22 (04): : 387 - 390
  • [4] Exploring Prognostic Implications of Socioeconomic Status in Patients With Peripheral Arterial Disease
    Leveille, Nayla
    Chen, Mia
    Nauche, Benedicte
    Drudi, Laura M.
    CIRCULATION, 2022, 146
  • [5] Evaluation of peripheral and uterine immune status of chronic endometritis in patients with recurrent reproductive failure
    Li, Yuye
    Yu, Shuyi
    Huang, Chunyu
    Lian, Ruochun
    Chen, Cong
    Liu, Su
    Li, Longfei
    Diao, Lianghui
    Markert, Udo R.
    Zeng, Yong
    FERTILITY AND STERILITY, 2020, 113 (01) : 187 - +
  • [6] Study on immune status alterations in patients with sepsis
    Cui, Zhiwen
    Wang, Lirui
    Li, Hongbin
    Feng, Min
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2023, 118
  • [7] A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas
    Forsyth, Peter
    Roldan, Gloria
    George, David
    Wallace, Carla
    Palmer, Cheryl Ann
    Morris, Don
    Cairncross, Gregory
    Matthews, Maureen Vallee
    Markert, James
    Gillespie, Yancey
    Coffey, Matt
    Thompson, Brad
    Hamilton, Mark
    MOLECULAR THERAPY, 2008, 16 (03) : 627 - 632
  • [8] Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study
    Lassman, Andrew B.
    Sepulveda-Sanchez, Juan Manuel
    Cloughesy, Timothy F.
    Gil-Gil, Miguel J.
    Puduvalli, Vinay K.
    Raizer, Jeffrey J.
    De Vos, Filip Y. F.
    Wen, Patrick Y.
    Butowski, Nicholas A.
    Clement, Paul M. J.
    Groves, Morris D.
    Belda-Iniesta, Cristobal
    Giglio, Pierre
    Soifer, Harris S.
    Rowsey, Steven
    Xu, Cindy
    Avogadri, Francesca
    Wei, Ge
    Moran, Susan
    Roth, Patrick
    CLINICAL CANCER RESEARCH, 2022, 28 (11) : 2270 - 2277
  • [9] A PILOT-STUDY OF THE TREATMENT OF PATIENTS WITH RECURRENT MALIGNANT GLIOMAS WITH INTRATUMORAL Y-90 RADIOIMMUNOCONJUGATES
    HOPKINS, K
    CHANDLER, C
    BULLIMORE, J
    SANDEMAN, D
    COAKHAM, H
    KEMSHEAD, JT
    RADIOTHERAPY AND ONCOLOGY, 1995, 34 (02) : 121 - 131
  • [10] A phase I trial of intratumoral (IT) administration of reovirus in patients with histologically confirmed recurrent malignant gliomas (MG)
    Forsyth, P. A.
    Roldan, G.
    George, D.
    Wallace, C.
    Morris, D. G.
    Cairncross, G.
    Matthews, M. Vallee
    Markert, J.
    Gillespie, Y.
    Coffey, M.
    Thompson, B.
    Hamilton, M.
    NEURO-ONCOLOGY, 2006, 8 (04) : 442 - 442